Tadalafil,
does it really help with Improved erectile function and intercourse success in men with erectile dysfunction?
research showsTadalafil is rated B because it consistently improves erectile function and intercourse success in men with erectile dysfunction. An integrated analysis of 2,102 men in 11 double-blind placebo-controlled trials found that on-demand 10- and 20-mg tadalafil improved the IIEF erectile-function domain and SEP2 and SEP3, while six once-daily trials involving 1,913 men found clinically meaningful gains in successful intercourse and IIEF-EF with 2.5 and 5 mg. These validated patient-reported symptom and encounter-diary outcomes directly measure clinical efficacy in erectile dysfunction, although tadalafil does not treat cardiovascular, hormonal, neurologic, or relationship causes. This is distinct from verdict 590 on tadalafil 5 mg for BPH/LUTS. Headache, flushing, dyspepsia, the absolute contraindication with nitrates, and cardiovascular assessment remain separate safety issues.
ads claimPromotion can turn a long half-life into claims of restored natural erections, higher libido, or correction of the cause. Tadalafil instead increases the likelihood of an erectile response and successful intercourse during sexual stimulation, with individual response and cause assessment still required.
Useful facts when choosing a product
- Tadalafil is a prescription PDE5 inhibitor used for erectile dysfunction either on demand or in a lower-dose once-daily regimen. The prescribed dose and interval take priority.
- Sexual stimulation is required, and the drug does not directly increase libido or remove vascular, neurologic, hormonal, or psychosocial causes of erectile dysfunction.
- Headache, flushing, dyspepsia, nasal congestion, back pain, and myalgia can occur; priapism or sudden visual or hearing change requires urgent care.
- Combining tadalafil with nitrates such as nitroglycerin is contraindicated because profound hypotension can occur. Recent cardiovascular events, unstable heart disease, alpha blockers, and strong CYP3A4 inhibitors require clinician review.
What the research actually shows
Carson and colleagues pooled 2,102 men from 11 twelve-week double-blind trials and reported that on-demand tadalafil 10 and 20 mg improved IIEF-EF by 6.5 and 8.6 points, with superior SEP2 and SEP3 outcomes versus placebo. Porst and colleagues integrated six randomized placebo-controlled trials involving 1,913 men and found significant improvements in IIEF-EF and SEP3 with once-daily 2.5 and 5 mg across several severities and comorbidities. A Western European trial also reported successful intercourse in 73.9% of attempts with on-demand tadalafil 20 mg versus 29.9% with placebo. This evidence concerns erectile-dysfunction symptoms and is separate from BPH/LUTS, nocturia, or treatment of underlying cardiovascular disease.
Why this is classified as B (74)
Multiple placebo-controlled trials and integrated analyses of 2,102 and 1,913 men consistently improved IIEF erectile function and SEP2 or SEP3, supporting B. The validated intercourse outcomes are direct to the disorder, but treatment does not correct causes and industry sponsorship is concentrated, giving B with 74 points. Nitrate contraindication and cardiovascular precautions are independent safety issues.
Counterpoint. If response is inadequate, clinicians should review correct use and sufficient attempts and assess testosterone deficiency, diabetes, vascular disease, medicines, and psychological or relationship factors. The dose should not be increased without direction or combined with nitrates.
Rejudgment record. New verdict — Centered the rating on replicated direct IIEF-EF and SEP2 or SEP3 symptom improvements in placebo-controlled trials, while accounting for patient-reported outcomes, concentrated industry funding, and the absence of underlying-cause treatment
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved erectile function in men with erectile dysfunction | B | IIEF-EF improvement was replicated across placebo-controlled trials and doses, but it does not treat the underlying cause. |
| Improved penetration success in men with erectile dysfunction | B | SEP2 improvement versus placebo was repeated, and sexual stimulation is required. |
| Improved successful-intercourse rate in men with erectile dysfunction | B | SEP3 improved with both on-demand and once-daily use and is separate from efficacy for BPH or nocturia. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Carson CC et al. 2004 | Integrated analysis of 11 randomized double-blind placebo-controlled trials | 2,102 | Tadalafil developer support and author industry ties | IIEF-EF and SEP2 or SEP3 | On-demand 10 and 20 mg significantly improved erectile function, penetration success, and successful intercourse versus placebo. | Large replicated direct symptom evidence |
| Porst H et al. 2014 | Integrated analysis of six randomized double-blind placebo-controlled trials | 1,913 | Eli Lilly support and employee coauthors | IIEF-EF and SEP3 successful intercourse | Once-daily 2.5 and 5 mg both produced significant and clinically meaningful improvements versus placebo. | Consistency across regimen and subgroups |
| Salonia A et al. 2021 EAU guideline | Evidence review and clinical guideline on male sexual dysfunction | 5 | European Association of Urology | Erectile-dysfunction efficacy, safety, and treatment sequence | Recommends PDE5 inhibitors as first-line drug therapy for erectile dysfunction when not contraindicated. | Independent clinical context |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Tadalafil x improved erectile function and intercourse success in men with erectile dysfunction — Evidence Grade B·74. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/tadalafil-erectile-dysfunction-erectile-function-intercourse-success/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.